WINTAC LIMITED was established as an offspring of Bangalore Pharmaceuticals and Research Laboratories Private Limited under the name of RECON LIMITED. In 2001, the name of the company was changed to Wintac Limited. The Company is engaged in the business of manufacturing goods and all its other activities revolve around this business. The company’s range of specialties includes Large and small-volume injectable and Ophthalmic solutions.
The delisting open offer for shares of WINTEC LIMITED was successful as per Regulation 17 of the Delisting Regulations at an exit price of `350 per share under the Reverse Book Building Process. The BSE vide its’ notice no. 20201211-16 dated December 11, 2020, communicated that the trading in the Equity Shares of the Company WINTEC LIMITED (Scrip Code: 524758) will be discontinued from December 18, 2020, and the scrip will be delisted from Exchange records with effect from December 28, 2020.
Wintac Limited provides outsourcing for sterile pharmaceutical products and Ophthalmic Solutions. Wintac Limited takes care of its customers from formulation development to commercial manufacturing.
The product range of the company includes a wide range of ophthalmic preparations and Injectables of Large and small volume parenteral.
The equity shares of the company have been delisted from the Bombay Stock Exchange of India on December 28, 2020.
Wintac Share Price, Share Details as of March 31, 2020
|
Wintac Outstanding Shares: |
10024242 |
|
Face Value of Wintac Share |
Rs. 10/- Per Equity Share |
|
ISIN of Wintac Share |
INE812C01016 |
|
Lot Size of Wintac Share |
100 |
|
Wintac Share Price |
Best In Industry |
|
PAN Number of Wintac |
AAACR8613H |
|
GST Number of Wintac |
29AAACR8613H1Z8 |
CIN of Wintac Limited |
U85110KA1990PLC011166 |
Registration Date of Wintac Limited |
23 August 1990 |
Category/Sub-category of Wintac Limited |
Public Limited |
Wintac Limited Registered office address and contact details |
54/1, BOODHIHAL, NELAMANGALA, BENGALURU - 562123. PH:- 080-67086500 |
Wintac Limited Registrar and Transfer Agent address and contact details |
CANBANK COMPUTER SERVICES LTD., NO.218, J.P.ROYALE, II MAIN, SAMPIGE ROAD, MALLESWARAM, BANGALORE - 560003. PH: 080-23469661/9662 |
|
Name and Description of main products/services |
NIC Code of the product/service |
% to the total turnover of the Company |
|
Formulation Sales |
99532693 |
80.65% |
|
Manufacturing Charges |
99532693 |
0.21% |
|
Formulation Development |
99839390 |
19.14% |
Shri S.T.R. Mady (Chairman)
Shri S. Jayaprakash Mady (Director)
Shri R.A. Thirumoorti (Director)
Dr. K. Paranjothy (Director)
Ms. S. Nanthitha (Additional Director)
Mr. Arshad Kagalwalla (Additional Director)
Shri Sunil B. Gundewar (Manager & C.O.O)
Shri B.P. Thyagaraj V.P. (Finance) & Secretary
Wintac Limited does not have any subsidiary or associate company.
|
S. No. |
Shareholders’ Name |
Number of shares |
% of total Shares of the company |
|
1 |
VEEGO Pharma LLC (Promoter) |
92,40,346 |
92.18% |
|
2 |
Public Shareholding |
7,83,896 |
7.82% |
|
|
Total |
1,00,24,242 |
100.00% |
Indian Pharmaceutical market ranks as 3rd largest in the world in terms of volume and 14th largest in terms of value. Healthcare has become one of the largest sectors of the Indian economy, in terms of both employment and revenue. India is known as the Pharmacy of the world and is the largest provider of generic drugs at a global level. The pharmaceutical industry of India supplies over 50% of the global demand for various vaccines, 40% of generic demands in the USA, and 25% of all the medicines in the United Kingdom. Excellent Research & Development, low cost of labor, availability of management and technical personnel, and local equipment availability has helped India to manufacture pharma products at a very low cost.
The Indian healthcare market may see a 3 fold jump in terms of value to reach US$ 372 billion by FY 2022. The growth can be attributed to rising income, greater health awareness, increased precedence of lifestyle disease, and Indian prominence in making medicinal products for the treatment of COVID 19. India aims to achieve vaccination for COVID-19 of 30 Crore people in the next few months.
Export of Pharmaceuticals products from India stood at US$ 16.8 billion in FY 2020 and US$ 2.07 billion in the month of October 2020. In the first 3 quarters of FY 2021, India exported pharmaceuticals worth US$ 15.86 billion. India supplied around 45 tons and 400 million tablets of hydroxychloroquine to around 114 countries globally to treat the covid patients in the initial stage of the covid-19 pandemic. Exports in FY 2021 of Indian pharma products are expected to cross US$ 24 billion, increasing by over 16% when compared to FY 2020.
After the onset of COVID 19, the Indian pharmaceutical sector became the busiest sector in the Indian economy. The pandemic proved to be a boon in disguise for the Indian pharmaceutical sector.
FAQS ON WINTAC LTD DELISTED STOCK
Q1) In which sector does Wintac Limited operate?
Wintac Limited operates in the Pharma sector.
Q2) Who is the principal promoter of Wintac Limited?
Veego Pharma is the principal promoter of Wintac Limited.
Q3) From where i can find the Wintac share price?
You can easily find Wintac share price on wwipl.com or contact us
Q4) What is the scrip name of Wintac Limited?
WINTAC
Q5) Is Wintac limited share buying worth it?
With the growth of the pharmaceutical sector in India, there is a huge amount of growth prospects for Wintac Limited as well.
SectorFinancial Service
LTP 1010.00 (+ 1.10 %)
Market Cap 80,190.32 Crore
EPS 30.99
PE32.59
BV 187.41
P/BV 5.39
FV 10
Shares793,963,539
SectorFinancial Service
LTP 9999.00 (-2.45 %)
Market Cap 15,893.01 Crore
EPS 598.25
PE16.71
BV 1276.69
P/BV 7.83
FV 10
Shares15,894,600
SectorFinancial Service
LTP 14.50 (-3.33 %)
Market Cap 8,754.90 Crore
EPS 0.22
PE65.91
BV 2.13
P/BV 6.81
FV 1
Shares6,037,864,375
SectorFinancial Service
LTP 7.75 (-3.13 %)
Market Cap 4,650.17 Crore
EPS -0.03
PE-
BV 0.40
P/BV 19.38
FV 1
Shares6,000,217,033
SectorFinancial Service
LTP 1650.00 (-2.94 %)
Market Cap 408,375.00 Crore
EPS 33.56
PE49.17
BV 96.87
P/BV 17.03
FV 1
Shares2,475,000,000
